**Supplementary Table S3. Baseline characteristics in patients with high
METoverexpression (IHC 3+).**

|  |  |  |
| --- | --- | --- |
| **Baseline characteristics** | **Tepotinib + gefitinib(*n* = 19)** | **Chemotherapy(*n* = 15)** |
| Median age, years (range) | 53.4 (42–76) | 59.8 (42–82) |
| Sex, n (%) | Female | 13 (68.4) | 7 (46.7) |
| Male | 6 (31.6) | 8 (53.3) |
| Smoking status, n (%) | Never  | 14 (73.7) | 11 (73.3) |
| Former | 4 (21.1) | 3 (20.0) |
| Current  | 1 (5.3) | 1 (6.7) |
| ECOG PS, n (%) | 0 | 4 (21.1) | 4 (26.7) |
| 1 | 15 (78.9) | 11 (73.3) |
| MET status, n (%) | *MET*amp | 11 (57.9) | 6 (42.9) |
| *MET* GCN ≥5 | 10 (52.6) | 6 (42.9) |
| *MET*:*CEP7* ≥2 | 7 (36.8) | 5 (35.7) |
| MET IHC 3+ | 19 (100) | 15 (100) |
| Prior EGFR TKI | TKI, n (%) |  |  |
| Gefitinib | 11 (57.9) | 11 (73.3)    |
| Afatinib | 3 (15.8) | 2 (13.3) |
| Erlotinib | 3 (15.8) | 2 (13.3) |
| Icotinib | 2 (10.5) | 0 |
| Median duration, months (range) | 11.0 (3.7–54.0) | 9.5 (6.2–20.2) |

Abbreviations: CEP7, centromere of chromosome 7; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; GCN, gene copy number; IHC, immunohistochemistry; MET, mesenchymal–epithelial transition factor; *MET*amp, *MET* amplification; TKI, tyrosine kinase inhibitor.